|
業務類別
|
Biotechnology |
|
業務概覽
|
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. |
| 公司地址
| 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071 |
| 電話號碼
| +1 678 620-3186 |
| 傳真號碼
| +1 770 864-1327 |
| 公司網頁
| https://www.galectintherapeutics.com |
| 員工數量
| 9 |
| Mr. Jack W. Callicutt |
Chief Financial Officer and Principal Accounting Officer |
美元 400.00K |
22/10/2025 |
| Dr. Khurram Jamil, M.D. |
Chief Medical Officer |
美元 500.00K |
22/10/2025 |
| Mr. Joel Lewis |
Director, President and Chief Executive Officer |
美元 624.00K |
31/03/2026 |
|
|
| Dr. Gilbert S. Omenn,M.D.,PhD |
Independent Director |
31/03/2026 |
| Dr. Gilbert F. Amelio,PhD |
Independent Director |
31/03/2026 |
| Dr. Henry Brem |
Independent Director |
17/03/2026 |
| Dr. Harold H. Shlevin,PhD |
Independent Director |
31/03/2026 |
| Mr. Kevin D. Freeman |
Independent Director |
31/03/2026 |
| Mr. Kary Eldred |
Independent Director |
31/03/2026 |
| Mr. Richard E. Uihlein |
Chairman of the Board |
31/03/2026 |
| Mr. Joel Lewis |
Director, President and Chief Executive Officer |
31/03/2026 |
| Dr. Benjamin S. Carson,Sr,M.D. |
Director |
31/03/2026 |
| Dr. Elissa J. Schwartz, PhD |
Independent Director |
31/03/2026 |
| Mr. Richard A. Zordani |
Independent Director |
31/03/2026 |
|
|
|
|
